Bionomics Ltd.
OTCQB: BNOEF
Company Overview
Bionomics (ASX: BNO) (OTCQB: BNOEF) is a global, clinical stage biopharmaceutical company leveraging its proprietary platform technologies to discover and develop a deep pipeline of best in class, novel drug candidates. Bionomics’ lead drug candidate BNC210 is a novel, proprietary negative allosteric modulator of the alpha-7 (α7) nicotinic acetylcholine receptor. Beyond BNC210, Bionomics has a strategic partnership with MSD (known as Merck & Co in the US and Canada) and a pipeline of clinical-stage ion channel programs targeting pain, depression, cognition and epilepsy.
Financial Highlights
$2,194,059
Revenue (ttm)
-$2,635,298
Gross Profit (ttm)
$0.00
Diluted EPS (ttm)
Management Team
Dr. Errol B. De Souza
Exec. Chairman
Mr. Adrian Hinton
Acting Chief Financial Officer
Prof. Paul Rolan
Consultant Chief Medical Officer of Clinical Neuroscience
Ms. Suzanne Irwin B.Com., FCIS
Company Sec.
Key Highlights
Market Capitalization
$0
Shares Outstanding
0
Shares Short (% of Float)
0 (0%)
Insider Ownership
4%